Moore Capital Management’s Crescent Biopharma CBIO Stock Holding History

Moore Capital Management’s Portfolio CBIO Stock Details CBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$459K	Hold	25,000	–	–	0.01%	422
2025 Q4	$297K	Buy	+25,000	New	+$318K	﹤0.01%	524
2019 Q3	–	Sell	-500	Closed	-$596K	–	342
2019 Q2	$596K	Hold	500	–	–	0.01%	264
2019 Q1	$623K	Hold	500	–	–	0.02%	248
2018 Q4	$474K	Hold	500	–	–	0.02%	193
2018 Q3	$720K	Sell	500 -500	-50%	-$756K	0.02%	238
2018 Q2	$1.61M	Sell	1,000 -225	-18%	-$387K	0.04%	195
2018 Q1	$1.99M	Buy	+1,225	New	+$2.55M	0.04%	173

Other funds holding CBIO

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Moore Capital Management's CBIO Position: Q1 2026 in Review

Moore Capital Management held its Crescent Biopharma (CBIO) position steady in Q1 2026 at 25,000 shares worth $459K. The position accounts for 0.01% of the portfolio, ranked #422.

Moore Capital Management first reported a position in CBIO in Q1 2018 and has held it in 8 quarters since. The position peaked at $1.99M in Q1 2018. 63 funds tracked by Wall St. Rank hold CBIO as of Q1 2026.

Moore Capital Management held 25,000 shares of Crescent Biopharma worth $459K as of Q1 2026.
Moore Capital Management left its Crescent Biopharma share count unchanged in Q1 2026.
Crescent Biopharma made up 0.01% of Moore Capital Management's portfolio in Q1 2026, its #422 holding.
Moore Capital Management first reported a position in Crescent Biopharma in Q1 2018 and has held it in 8 quarters since.
Moore Capital Management's Crescent Biopharma position peaked at $1.99M in Q1 2018.
63 funds tracked by Wall St. Rank held Crescent Biopharma as of Q1 2026.

Based on Moore Capital Management's 13F filing for Q1 2026, filed 15 May 2026.